Global 
Sverige 
USA Stille AB: Year-end Report 2024
Stille AB (publ) today presents the report for the fourth quarter and full year 2024.
Revenue amounted to MSEK 159.8 (77.3) driven by strong organic growth in surgical instruments, the successful acquisition of Fehling and solid growth in the US. Total growth amounted to 106.4 percent, of which 22.0 percent was organic growth.
“Earnings growth remains solid with an adjusted EBITDA margin of 28.4 percent.”, says Torbjörn Sköld and comments on the company’s strategic portfolio review where it was decided to phase out the table platform GS2 with a negative non-recurring effect of MSEK 24.1, “The decision is in line with our focus on high quality premium products for niche clinical segments and gives us the opportunity to focus on the recently launched imagiQ3 Legacy”.
The gross profit amounted to 57.1 percent (45.6) and EBITDA before non-recurring items amounted to MSEK 45.4 (17.7).
”2024 ended on a high note – our products are delivering value to our customers, which is creating favorable demand, strong growth and a healthy cash flow.”, concludes Stille’s CEO.
| MSEK | OCT-DEC 2024 |
OCT-DEC 2023 |
JAN-DEC 2024 |
JAN-DEC 2023 |
| Net sales | 159.8 | 77.3 | 569.9 | 294.9 |
| Gross profit, % | 57.1 | 45.6 | 51.9 | 44.8 |
| EBITDA before non-recurring items | 45.4 | 17.7 | 145.2 | 62.6 |
| EBITDA before non-recurring items, % | 28.4 | 22.8 | 25.5 | 21.2 |
| EBITDA | 20.9 | 17.7 | 100.8 | 59.3 |
| EBITDA, % | 13.1 | 22.8 | 17.7 | 20.1 |
| EBIT before non-recurring items | 35.5 | 14.0 | 114.9 | 48.3 |
| EBIT before non-recurring items, % | 22.2 | 18.1 | 20.2 | 16.4 |
| EBIT | 11.1 | 14.0 | 70.5 | 45.0 |
| EBIT, % | 6.9 | 18.1 | 12.4 | 15.2 |
Torshälla, February 13th, 2025.
